Merck & Company, Inc. (MRK) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. At $112.72, A.R:R 0.6:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.1%; Weak growth.
Merck is a global pharmaceutical company with Pharmaceutical (human health drugs and vaccines) and Animal Health segments generating $65B in total sales in 2025. Keytruda (anti-PD-1 oncology) dominates at 49% of company-wide sales, with Gardasil/Gardasil 9 second at $5.2B.... Read more
Sell if holding. At $112.72, A.R:R 0.6:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.1%; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.
Passes 4/6 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductKeytruda49%10-K Item 1A: 'in 2025, sales of Keytruda represented 49% of the Company's total sales'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $112.72, A.R:R 0.6:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Thin upside margin: 3.1%; Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $107.01. Score 5.2/10, moderate confidence.
Take-profit target: $116.77 (+3.1% upside). Prior stop was $107.01. Stop-loss: $107.01.
Thin upside margin: 3.1%; Weak growth; Negative momentum.
Merck & Company, Inc. trades at a P/E of 15.0 (forward 11.2). TrendMatrix value score: 6.0/10. Verdict: Sell.
35 analysts cover MRK with a consensus score of 3.9/5. Average price target: $130.
What does Merck & Company, Inc. do?Merck is a global pharmaceutical company with Pharmaceutical (human health drugs and vaccines) and Animal Health...
Merck is a global pharmaceutical company with Pharmaceutical (human health drugs and vaccines) and Animal Health segments generating $65B in total sales in 2025. Keytruda (anti-PD-1 oncology) dominates at 49% of company-wide sales, with Gardasil/Gardasil 9 second at $5.2B. Products are sold to drug wholesalers, hospitals, managed care, and government agencies worldwide.